Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Garber

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Journal of Medicinal Chemistry|June 19, 1998
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analoguesG V De Lucca, U T Kim, J Liang, et al.
Journal of Medicinal Chemistry|May 23, 2000
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitorsJ W Corbett, S S Ko, J D Rodgers, et al.
Journal of Medicinal Chemistry|May 9, 1997
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysisD A Nugiel, K Jacobs, L Cornelius, et al.
Journal of the American Heart Association|January 22, 2026
Sex and Racial Differences in Left Atrial Appendage MorphologyAhmed Wahaj, Madeline E Mauri, Matthew J Bocchese, et al.
Chemistry & Biology|November 18, 1998
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitorsJ D Rodgers, P Y Lam, B L Johnson, et al.
Chemistry & Biology|April 1, 1996
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450C N Hodge, P E Aldrich, L T Bacheler, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Journal of Medicinal Chemistry|June 19, 1998
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analoguesG V De Lucca, U T Kim, J Liang, et al.
Journal of Medicinal Chemistry|May 23, 2000
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitorsJ W Corbett, S S Ko, J D Rodgers, et al.
Journal of Medicinal Chemistry|May 9, 1997
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysisD A Nugiel, K Jacobs, L Cornelius, et al.
Journal of the American Heart Association|January 22, 2026
Sex and Racial Differences in Left Atrial Appendage MorphologyAhmed Wahaj, Madeline E Mauri, Matthew J Bocchese, et al.
Chemistry & Biology|November 18, 1998
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitorsJ D Rodgers, P Y Lam, B L Johnson, et al.
Chemistry & Biology|April 1, 1996
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450C N Hodge, P E Aldrich, L T Bacheler, et al.
Pageof 9